The Ilex Group has been leading the way in the field of in-vitro diagnostics since 1977. Publicly traded on the Tel Aviv Stock Exchange since 1995 (TASE:ILX), the Ilex Group is the largest supplier of in vitro diagnostic equipment, reagents, laboratory management software, blood bank diagnostic kits, and diagnostic support services to the healthcare establishment in Israel and a rapidly-expanding player in emerging markets like Africa, Turkey, Eastern Europe, Russia and CIS.
With over 100 employees worldwide, most of whom are university graduates, and offices on three continents, the Ilex Group is closely affiliated with leading multinational medical conglomerates like Abbott Diagnostics, Novartis, Gen-Probe, bioMerieux, CH-Werfen Instrumentation Laboratory and others. Major clients include the Israeli Ministry of Health, all four major Israeli HMOs (serving seven million members), diabetes clinics and medical research institutions, the Israeli Defense Forces Medical Corps, major public and private health organizations in South Africa and blood banks in Israel, South Africa, Turkey and Russia.
Leveraging three decades of market experience and success, a top-tier multidisciplinary management team, and solid local and international reputation and market presence, the Ilex Group is well-positioned to assume a leadership role in the growing field of advanced in-vitro diagnostics.
The Ilex representative in Russia is currently installing a Tigris system for testing Blood donations in Moscow.
Latelty, Ilex Biotech, a fully owened subsidiary of Ilex Medical, has won the Israeli national tender for NAT testing of blood donations. Israel has one centreliezed blood center. The routine testing will start on January first 2008.
The evaluation of an Immucor Echo system for Blood typing was successfully concluded. Ilex South Africa is now authorized to install the system in blood banks and hospitals in which blood donation are collected.
Prostate cancer gene 3 (PCA3) is a new gene-based test produced by Gen-Probe, performed on a urine sample. PCA3 is highly specific to Prostate Cancer (PCA) and therefore, in contrast to PSA, not increased by conditions such as benign enlargement or inflammation of the prostate. If you are concerned about PCA because of an elevated PSA or are feeling insecure about a previously performed (negative) biopsy, the PCA3 urine test can provide additional information that may help you and your doctor to decide whether a (new) biopsy is really needed.
